Study S001048

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06820281
Acronym: TIRTLE2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 44
Start: 2026-07-07
Primary completion: 2027-12-31
Lead sponsor: Victor Chang Cardiac Research Institute
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG:Tirzepatide 2.5mg weekly; DRUG:Placebo injection (normal saline)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Whole-body insulin sensitivity [6 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014500	Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Snaith JR, Diabetes care	2026	Randomized trial	PMID 41264593 DOI	registry reference BACKGROUND:41264593